Arcutis Biotherapeutics, Inc.

NasdaqGS:ARQT Stock Report

Market Cap: US$2.1b

Arcutis Biotherapeutics Management

Management criteria checks 4/4

Arcutis Biotherapeutics' CEO is Frank Watanabe, appointed in Jan 2016, has a tenure of 9.67 years. total yearly compensation is $3.69M, comprised of 17.9% salary and 82.1% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth $13.24M. The average tenure of the management team and the board of directors is 3.5 years and 5.1 years respectively.

Key information

Frank Watanabe

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage17.91%
CEO tenure9.7yrs
CEO ownership0.6%
Management average tenure3.5yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate

Aug 23

Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load?

Jul 15
Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load?

Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

May 09
Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
User avatar

FDA PDUFA Date And Payer Expansion Will Unlock Opportunity

Expanding ZORYVE's indications and payer coverage is expected to significantly boost revenue and market potential.

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets

Apr 19

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute

Mar 12

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up

Mar 09
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up

Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations

Feb 26

Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period

Jan 23

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Jan 02
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump

Nov 27
There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Nov 15

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Sep 23
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Jul 17
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Jun 21
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

May 24
Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

May 20

Arcutis Biotherapeutics: Betting Big On Zoryve

May 01

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25
New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Mar 03
Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Feb 28
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

CEO Compensation Analysis

How has Frank Watanabe's remuneration changed compared to Arcutis Biotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$93m

Mar 31 2025n/an/a

-US$130m

Dec 31 2024US$4mUS$661k

-US$140m

Sep 30 2024n/an/a

-US$196m

Jun 30 2024n/an/a

-US$199m

Mar 31 2024n/an/a

-US$217m

Dec 31 2023US$5mUS$634k

-US$262m

Sep 30 2023n/an/a

-US$268m

Jun 30 2023n/an/a

-US$331m

Mar 31 2023n/an/a

-US$327m

Dec 31 2022US$5mUS$590k

-US$311m

Sep 30 2022n/an/a

-US$311m

Jun 30 2022n/an/a

-US$260m

Mar 31 2022n/an/a

-US$235m

Dec 31 2021US$4mUS$525k

-US$206m

Sep 30 2021n/an/a

-US$169m

Jun 30 2021n/an/a

-US$150m

Mar 31 2021n/an/a

-US$144m

Dec 31 2020US$3mUS$442k

-US$136m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$90m

Mar 31 2020n/an/a

-US$63m

Dec 31 2019US$1mUS$390k

-US$42m

Sep 30 2019n/an/a

-US$35m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$634kUS$327k

-US$19m

Compensation vs Market: Frank's total compensation ($USD3.69M) is below average for companies of similar size in the US market ($USD5.53M).

Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.

CEO

Frank Watanabe (57 yo)

9.7yrs
Tenure
US$3,689,491
Compensation

Mr. Todd Franklin Watanabe, also known as Frank, M.A., serves as Director of Amunix Pharmaceuticals, Inc. since June 2021. He has been President of Arcutis Biotherapeutics, Inc. (Formerly known as Arcutis...

Leadership Team

NamePositionTenureCompensationOwnership
Todd Watanabe
President9.7yrsUS$3.69m0.62%
$ 13.2m
Bhaskar Chaudhuri
Co-Founder & Independent Directorno dataUS$315.00k0.75%
$ 16.1m
Masaru Matsuda
Senior VP3.7yrsUS$1.74m0.074%
$ 1.6m
Patrick Burnett
Executive VP & Chief Medical Officer5.1yrsUS$2.51m0.087%
$ 1.9m
Larry Edwards
Executive VP & Chief Commercial Officer2yrsUS$1.97m0.052%
$ 1.1m
Latha Vairavan
Chief Financial Officerless than a yearno data0.015%
$ 329.8k
Rajvir Madan
Chief Digital & Technology Officer3.9yrsno datano data
Amanda Sheldon
Head of Corporate Communications4.1yrsno datano data
Kent Taylor
Senior Vice President of Sales2.7yrsno datano data
Aleen Hosdaghian
Vice President of Marketingless than a yearno datano data
Todd Tucker
Senior VP & Chief Human Resources Officer3.5yrsno datano data
Bethany Dudek
Chief Technical Officer1.8yrsno datano data
3.5yrs
Average Tenure
57yo
Average Age

Experienced Management: ARQT's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Todd Watanabe
President8.7yrsUS$3.69m0.62%
$ 13.2m
Bhaskar Chaudhuri
Co-Founder & Independent Director9.4yrsUS$315.00k0.75%
$ 16.1m
Patrick Heron
Independent Director9.4yrsUS$336.98k0.035%
$ 762.4k
Keith Leonard
Independent Chairman of the Board4yrsUS$313.02k0.0087%
$ 187.0k
Terrie Curran
Independent Director4.8yrsUS$310.00kno data
Halley Gilbert
Independent Director5.3yrsUS$310.00k0.0072%
$ 155.7k
Howard Welgus
Independent Director5.1yrsUS$307.13k0.077%
$ 1.7m
Sue-Jean Lin
Independent Director4.3yrsUS$325.00k0.0075%
$ 161.2k
Neha Krishnamohan
Independent Director3yrsUS$310.00k0.013%
$ 282.3k
5.1yrs
Average Tenure
57yo
Average Age

Experienced Board: ARQT's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/10 17:15
End of Day Share Price 2025/09/10 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcutis Biotherapeutics, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chris ShibutaniGoldman Sachs
Richard J. LawGoldman Sachs
null nullGuggenheim Securities, LLC